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Several studies have explored the predictability of placebo and nocebo individual
responses by investigating personality factors and expectations of pain decreases
and increases. Psychological factors such as optimism, suggestibility, empathy and
neuroticism have been linked to placebo effects, while pessimism, anxiety and
catastrophizing have been associated to nocebo effects. We aimed to investigate
the interplay between psychological factors, expectations of low and high pain and
placebo hypoalgesia and nocebo hyperalgesia. We studied 46 healthy participants
using a well-validated conditioning paradigm with contact heat thermal stimulations.
Visual cues were presented to alert participants about the level of intensity of an
upcoming thermal pain. We delivered high, medium and low levels of pain associated
with red, yellow and green cues, respectively, during the conditioning phase. During
the testing phase, the level of painful stimulations was surreptitiously set at the medium
control level with all the three cues to measure placebo and nocebo effects. We found
both robust placebo hypolagesic and nocebo hyperalgesic responses that were highly
correlated with expectancy of low and high pain. Simple linear regression analyses
showed that placebo responses were negatively correlated with anxiety severity and
different aspects of fear of pain (e.g., medical pain, severe pain). Nocebo responses
were positively correlated with anxiety sensitivity and physiological suggestibility with a
trend toward catastrophizing. Step-wise regression analyses indicated that an aggregate
score of motivation (value/utility and pressure/tense subscales) and suggestibility
(physiological reactivity and persuadability subscales), accounted for the 51% of the
variance in the placebo responsiveness.When considered together, anxiety severity, NEO
openness-extraversion and depression accounted for the 49.1% of the variance of the
nocebo responses. Psychological factors per se did not influence expectations. In fact,
mediation analyses including expectations, personality factors and placebo and nocebo
responses, revealed that expectations were not influenced by personality factors. These
findings highlight the potential advantage of considering batteries of personality factors
and measurements of expectation in predicting placebo and nocebo effects related to
experimental acute pain.
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INTRODUCTION
Personality factors can influence placebo and nocebo effects
(Colloca and Grillon, 2014; Colagiuri et al., 2015). Factors such
as dispositional optimism (Geers et al., 2005, 2007, 2010; Nes and
Segerstrom, 2006; Morton et al., 2009), hypnotic suggestibility
(De Pascalis et al., 2002), somatic focus (Geers et al., 2006;
Johnston et al., 2012), empathy (Colloca and Benedetti, 2009;
Hunter et al., 2014; Rütgen et al., 2015a,b), neuroticism (Peciña
et al., 2013), altruism (Peciña et al., 2013), social desirability
(Gelfland et al., 1965), dopamine-related traits (Schweinhardt
et al., 2009), fear of pain (Flaten et al., 2006; Zubieta et al., 2006;
Lyby et al., 2010), locus of ego-resilience (Peciña et al., 2013),
anxiety (Staats et al., 2001; Ober et al., 2012), pessimism (Geers
et al., 2005; Corsi et al., 2016), pain catastrophizing (Vogtle et al.,
2013), harm avoidance, and persistence (Corsi et al., 2016) have
been linked to placebo and nocebo effects.
In particular, optimism, the active behavioral and mental
coping ability of individuals to face adversity, has been liked to
proneness to show higher placebo analgesic effects (Geers et al.,
2005, 2007, 2010). Attention toward the body, referred as somatic
focus, is related to larger placebo analgesic effects and higher
positive expectations (Geers et al., 2006). Empathic resonance
and concern for others have been linked to placebo analgesia as
well (Colloca and Benedetti, 2009; Hunter et al., 2014; Rütgen
et al., 2015a,b). Hypnotic susceptibility and responsiveness to
verbal suggestions influence placebo analgesia (Huber et al.,
2013). Other factors such as Neuroticism-Extraversion-Openness
to experience (NEO), NEO Altruism, NEO Straightforwardness,
NEO Angry Hostility and Ego-Resiliency, have been coupled
with a 25% variance in behavioral placebo responses to pain and
27% of the µ-opioid system activation in the nucleus accumbens
(Peciña et al., 2013).
Conversely, anxiety (Staats et al., 2001), harm avoidance and
persistence (Corsi et al., 2016) and pain catastrophizing (Swider
and Babel, 2013; Vogtle et al., 2013) have been associated with
nocebo effects. Anxiety and harm avoidance correlate positively
with nocebo effects, while optimism and persistence correlate
negatively with nocebo effects in the context of the motor
system (Corsi et al., 2016). In the present study, our aim was to
investigate how distinct positive and negative personality factors
estimate the likelihood of placebo and nocebo effects. Moreover,
we aimed to establish the relationship among trial-by-trial
expectations of pain reduction and increase, and placebo/nocebo
effects, and personality. We hypothesized that using aggregated
personality factors and expectations would allow us to better
estimate placebo and nocebo responses in a laboratory setting
using a well-established conditioningmodel (Colloca et al., 2010).
MATERIALS AND METHODS
Study Participants
We recruited 50 participants from Baltimore, MD, USA to
enroll a total of 46 healthy participants (24 women; 27.41
± 1.07 years; see Table 1). Four participants were excluded:
two of them did not meet the inclusion criteria and two were
unable to discriminate distinct levels of heat thermal stimulation
TABLE 1 | Characteristics of study participants.
Characteristics of Participants
Sex 24 females
22 males
Age (years) 27.41 ± 1.07
Body Mass Index (BMI) 26.00 ± 0.71
Systolic blood pressure values (mmHg) 120.19 ± 2.00
Diastolic blood pressure (mmHg) 75.15 ± 1.27
Heart rate (beats per minute) 66.36 ± 1.45
Levels of pain (◦C) Low 41.51 ± 0.36
Medium 44.55 ± 0.36
High 47.52 ± 0.36
All values are expressed as mean ± SE.
that are used for the acquisition phase of the conditioning
paradigm. Upon arrival, participants signed a consent form to
study pain modulation. Participants with cardiovascular and
neurological diseases, family or personal history of psychiatric
conditions, personal history of drug abuse, acute or chronic
pain, color blindness, impaired hearing, pregnancy and current
use of painkillers and any other medication, were excluded
from participating in this study. On the day of the experiment, a
toxicology drug test was also performed to exclude any recent use
of marijuana, cocaine, opiates such as hydrocodone, oxycodone
and hydromorphone, amphetamine, methamphetamine,
ecstasy/MDMA and phencyclidine. Participants who reported
use of tobacco or nicotine over the last year were also excluded.
This study was carried out in accordance with the
recommendations of the UMB Institutional Review Board
with written informed consent from all subjects.
All subjects gave written informed consent in accordance with
the Declaration of Helsinki. The protocol was approved by the
UMB Ethics Committee (Prot # HP00065783). Due to the use of
deception, a debriefing written formwas given to each participant
at the end of the study participation offering to withdraw the data
from the study. None of them opted to do so. Participants were
compensated for their participation ($90).
Pain Assessment
A well-validated paradigm that has been previously described
(Colloca et al., 2010) was used to explore placebo and nocebo
responses to a contact heat thermal painful stimulation.
Individual pain sensitivity and tolerance were measured in
each participant using the ATS Medoc Pathway system (Medoc
Advanced Medical System, Rimat Yishai, Israel). A 3 × 3 cm
thermode was placed on the dominant forearm as confirmed by
the Edinburgh Handedness Inventory. The baseline temperature
delivered by the Medoc equipment was 32◦C. Ascending series of
stimulations starting fromwarm sensation tomaximum tolerable
pain were delivered, while the participant was asked to stop the
machine as soon as she felt a warm sensation, low, medium and
high pain. Each level was assessed four times and averaged to
determine the intensities of stimulations to be used during the
acquisition and testing phases of the conditioning paradigm. We
defined then the painful stimulations by subtracting 3 and 6◦C
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starting from the highest reported level of tolerable pain (e.g.,
49 and 43◦C) so that the levels of stimulation were standardized
among participants. The intensities of stimulation were also
rated to ensure correspondence to individual experience of low,
medium and high pain.
Placebo and Nocebo Manipulation
Three visual cues (red, yellow, and green) were displayed on a
computer placed one meter apart from a chair in a quiet lab.
Participants were told that the green, yellow and red lights would
anticipate the delivery of a low, medium and high level of pain,
respectively.
During the acquisition phase of the classical conditioning
paradigm, 18 painful stimulations were delivered at the three
levels of pain corresponding to an individual low, medium, and
high level of pain in association to six red, six yellow, and six
green cues, respectively. Afterwards, during the testing phase,
9 stimulations were paired with the three color cues but the
intensity was set at same medium control level in accordance
with a previously described paradigm (Colloca et al., 2010). The
sequence of the cue presentation was counterbalanced across
participants using four distinct sequences. This change in the
pain levels allowed us to explore how first-hand experience of low
and high pain during the acquisition phase results in placebo and
nocebo responses during the testing phase. Participants rated the
experienced pain immediately after the painful stimulation using
the VAS scale (from 0 = no pain to 100 = maximum tolerable
pain). Pain reports were collected using Celeritas Fiber Optic
Response System (Psychology Software Tools, Inc., Sharpsburg,
PA, USA).
Moreover, trial-by-trial expectations were measured. The
terms “expectation” and “expectancy” have been often used in an
interchangeable way. Herein, we adopted the term “expectation”
to refer to verbalized and measurable constructs as compared to
“expectancies” defining psychophysical predictions that can be
present without full awareness (i.e., implicit expectancies) (Kube
et al., 2017).
Participants were asked to rate their expectations of the
upcoming stimulation immediately before the delivery of the
thermal stimulation using a VAS anchored from 0 = no pain to
100=maximum tolerable pain.
During each trial, the visual cue was presented for 4 s.
Immediately after the presentation of the cue, participants
were asked to rate their expectation (5 s) about the upcoming
stimulus. The thermal stimulation lasted for 10 s. Then
participants were asked to rate their perceived pain (5 s) and
an inter-trial interval followed with a variable timing (8–10 s).
The procedure and the delivery of painful stimulations were
controlled by scripts pre-programmed in Eprime (Psychology
Software Tools, Inc., Sharpsburg, PA, USA; version 2.0). To
prevent habituation, the presentation of visual cues during both
phases was counterbalanced using four preprogramed sequences.
Psychological Questionnaires
Participants completed a comprehensive battery of psychological
questionnaires, which were chosen to cover distinct psychological
factors that we hypothesized to be linked to placebo and nocebo
effects. In particular, for the placebo-related factors, we included
optimism, reward, suggestibility, empathy and sensation-seeking
and motivation. We used the following questionnaires: (1) Life-
Orientation Test-Revisited, Lot-R (Scheier et al., 1994) to assess
generalized optimism vs. pessimism; (2) Behavioral Inhibition
and Behavioral Activation Scale, BIS/BAS (Carver and White,
1994) to investigate dispositional sensitivity to the behavioral
inhibition system (BIS) and the behavioral activation system
(BAS); (3) Multidimensional Iowa Suggestibility Scale, MISS
(Kotov et al., 2004) to investigate the main components of
suggestibility; (4) Interpersonal Reactivity Index, IRI (Davis,
1980) to measure the participant’s dispositional empathy in
different situations; (5) Sensation Seeking (SS) (Zuckerman,
1994) to measure the necessity to find and experience new
situations; (6) Tri-dimensional Personality Questionnaire, TPQ
(Cloninger et al., 1991) to assess novelty seeking (NS), harm
avoidance (HA), and reward dependence (RD); (7) and the
Intrinsic Motivation Inventory (IMI) (Markland and Hardy,
1997) to assess participants’ experience during the experimental
procedure that was just performed.
For the nocebo-related psychological factors included
measurements of various aspects of anxiety (e.g., state, severity,
and sensitivity), catastrophizing, neuroticism, fear of pain,
depression and feelings of worry. The following inventories
were used: (1) State and Trait Anxiety Inventory, STAI
(Spielberger, 1983) to investigate anxiety either in a precise
moment (STAI-Y1) or as a general tendency (STAI-Y2); (2)
Anxiety Sensitivity Index, ASI (Reiss et al., 1986) to assessed
beliefs of sensations that could have harmful consequences;
(3) Beck Anxiety Inventory, BAI (Beck et al., 1988) to measure
experience of anxiety symptoms during the previous 2 weeks;
(4) Beck Depression Inventory, BDI (Beck et al., 1961) to
include items relating to depression, cognitions, as well
as physical symptoms; (5) Mood and Anxiety Symptom
Questionnaire, MASQ (Haigh et al., 2011) to assess depressive
symptoms and anxiety symptoms; (6) Pain Catastrophizing
Scale, PCS (Sullivan et al., 1995) to assess catastrophizing
impacts on pain experience; (7) Neuroticism—Extroversion—
Openness Inventory (NEO)—Five Factory Inventory (FFI)
(Costa and McCrae, 1985, 1992) to investigate Neuroticism,
Extraversion, Openness to Experience, Agreeableness, and
Conscientiousness; (8) Fear of Pain Questionnaire, FOP
(Osman et al., 2002) to measure fear levels to different types
of physical pain; (9) Penn State Worry Questionnaire, PSWQ
(Meyer et al., 1990) to measure the trait of worry in different
situations.
We also administered the Positive and Negative Affective
Schedule, PANAS (Crawford and Henry, 2004), that investigates
the relationships between positive and negative affect with
personality states and emotions.
Statistical Analysis
VAS pain and VAS expectations ratings were compared using
repeated measure ANOVA. We tested for the main effect of
the factor condition (red, yellow, and green) and time (trials)
set both as within-subjects factors. F-tests were followed by the
Bonferroni post-hoc tests for multiple comparisons. We also
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tested for sex influences on placebo and nocebo effects using
sex as a between factor. Partial eta squared (η2) effect sizes are
reported for all the comparisons.
VAS pain and expectation scores from the testing phase were
further averaged across trials to calculate the difference between
yellow-green and yellow-red pain scores to be correlated with
placebo and nocebo effects, respectively.
The above psychological questionnaire scores were used in
both simple correlation and multivariate analyses. We analyzed
psychological questionnaire scores using both Spearman
correlation and stepwise multiple regression model analyses in
which the questionnaires were modeled to predict placebo and
nocebo responses. Mediation analyses were also calculated with
expectation as mediator (M), placebo (or nocebo) responses as
dependent variable (Y), and personality factors as independent
variable (X). For testing indirect effects, a bootstrapping method
based on resampling of 1,000 times was used in accordance with
Preacher and Hayes methods (Preacher and Hayes, 2004; Hayes
and Preacher, 2010). All the analyses were carried out using
the SPSS software package (SSPS Inc, Chicago, Illinois, USA,
vers.21). To minimize alpha errors, the level of significance was
set at p ≤ 0.005.
RESULTS
We performed separate analyses for the VAS pain and
expectation reports related to the acquisition and testing phases
of the conditioning paradigm.
Conditioning: Acquisition Phase
We analyzed the VAS pain reports during the acquisition phase,
and found that participants distinguished the low, medium and
high levels of painful stimuli [main effect of condition: F(2, 88)
= 503.970, p < 0.001, η2 = 0.920]. The average pain score for
red-associated stimuli was 74.73± 2.36 using an average intensity
of pain equal to 47.52◦C, the average pain score for yellow was
29.55 ± 1.54 using an average pain equal to 44.55◦C and the
average pain score for green was 9.37 ± 0.96 when an average
pain equal to 41.51◦C out of 50◦C was delivered. The factor time
was significant [F(5, 220) = 7.359, p < 0.001, η
2 = 0.143]. The
condition× time interaction was significant [F(10, 440) = 5.324, p
< 0.001, η2 = 0.108] (Figure 1A) showing a quadratic trajectory
[F(1, 44) = 10.308, p < 0.002, η
2 = 0.190].
FIGURE 2 | Time course of expectation ratings. Expectations during the
acquisition phase differed across the three conditions. During the testing
phase, expectations for high, medium and low pain continued to be staidly
different across the three conditions.
FIGURE 1 | Time course of placebo and nocebo responses (A). Representation trial-by-trial of the average of pain ratings for control (yellow), placebo (green)
and nocebo (red) responses during the acquisition (trials 1–6) and the testing (trials 7–9) phases. Participants learned to distinguish the low, medium and high levels of
painful stimuli over the acquisition phase. During the testing phase, there was a significant placebo and nocebo effect indicating no extinction over the entire
experimental session. Graphical representation of the pain score for the red, green, and yellow associated stimuli (B). The red associated stimuli were perceived as
higher than the yellow control stimuli and green were rated as lower than the yellow stimuli during the testing phases when the stimulation was surreptitiously set at a
medium level for the three colors indicating both robust placebo and nocebo effects. Data are expressed as mean ± sem. **p < 0.001.
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VAS expectation scores (75.63 ± 2.09, 34.74 ± 1.61,
and 11.30 ± 0.98, respectively) during the acquisition phase
differed across the three conditions [F(2, 88) = 515.152,
p < 0.001; η2 = 0.921], with significant time [F(5, 220)
= 3.392, p = 0.006; η2 = 0.072] and condition × time
interaction [F(10, 440) = 7.542, p < 0.001; η
2 = 0.146] effects
(Figure 2).
Conditioning: Testing Phase
During the testing phase, when the level of pain was set at
the same control (yellow) intensity for the three cues, VAS
pain reports revealed a significant effect of condition [F(2, 88)
FIGURE 3 | Distribution of placebo and nocebo effects. Each bar
represents a single study participant. The green bars represent the magnitude
of the placebo effect (yellow-green VAS scores). The red bars represent the
magnitude of the nocebo effect (yellow-red-VAS score). It is worth noting that
the individual placebo and nocebo responses range from no responses at all
to medium to large effect.
= 96.04, p < 0.001; η2 = 0.686], time [F(2, 88) = 7.553,
p = 0.001; η2 = 0.147] with a non-significant condition ×
time interaction [F(4, 176) = 0.378, p = 0.824; η
2 = 0.009]
indicating no extinction over the entire experimental session
(Figure 1A). Post-hoc Bonferroni tests indicated that the red
stimuli (average VAS: 46.98 ± 2.46) were perceived as higher
than the yellow control stimuli (average VAS: 29.96 ± 1.78)
(p < 0.001) and green (average VAS: 17.86 ± 1.70) were
rated as lower than the yellow stimuli (p < 0.001) indicating
both robust placebo and nocebo effects (Figure 1B). The
distribution and magnitude of placebo and nocebo responses
ranged from no effects to large changes in pain modulation
(Figure 3).
Placebo effects were significantly correlated with the
hypoalgesic effect experienced during the acquisition phase
(Placebo: r = 0.388, p = 0.008) but nocebo hyperalgesic
responses appeared to be independent of the experienced
high pain (r = 0.080, p = 0.598). Moreover, being
prone to experience a placebo response did not imply
being also prone to experience a nocebo response, as
indicated by the absence of significant correlation between
individual placebo and the nocebo responses (r = −0.113,
p= 0.454).
During the testing phase, expectations for high, medium and
low pain [70.61 ± 2.45, 33.87 ± 1.81, and 9.54 ± 0.93] were
different across the three conditions [F(2, 88) = 441.355, p <
0.001; η2 = 0.909] with a main effect of time [F(2, 88) = 8.092, p=
0.001; η2 = 0.155], and a significant interaction condition× time
[F(4, 176) = 13.156, p < 0.001; η
2 = 0.230] (Figure 3), showing
a linear trajectory [F(1, 44) = 33.850, p < 0.001, η
2 = 0.435].
Importantly, we found that positive expectations correlated with
placebo responses (r= 0.412, p= 0.002, Figure 4A) and similarly
negative expectations correlated with nocebo effects (r = 0.351,
p= 0.008, Figure 4B).
In this cohort of participants, sex effects for placebo, nocebo
and expectancies were not observed [placebo: F(1, 44) = 0.010,
p = 0.922; nocebo: F(1, 44) = 0.990, p = 0.325; positive
FIGURE 4 | Relation between expectations and placebo/nocebo effects. VAS expectation scores were collected on a trial-by-trial basis during the testing
phase. Expectation of low pain positively correlates with placebo effects (A). Similarly, expectation of upcoming high painful stimulation positively correlates with
nocebo effects (B).
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TABLE 2 | Correlations between placebo, nocebo and personality factors.
Personality factors PLACEBO EFFECT NOCEBO EFFECT
R p r p
STAI-Y1 pre −0.175 0.246 0.217 0.147
STAI-Y2 post −0.004 0.978 0.177 0.241
STAY2 −0.123 0.415 0.119 0.432
ASI −0.147 0.330 0.460 0.001
BAI −0.485 0.001 −0.028 0.855
BDI −0.039 0.796 0.244 0.102
PANAS total 0.096 0.527 0.175 0.245
PANAS positive −0.218 0.145 −0.199 0.429
PANAS negative −0.366 0.012 0.248 0.097
NEO neuroticism −0.166 0.270 0.021 0.892
NEO extraversion −0.349 0.018 0.186 0.217
NEO openness −0.228 0.128 −0.264 0.076
NEO agreeableness −0.098 0.518 0.091 0.548
NEO conscientiousness −0.001 0.993 0.054 0.720
MASQ General depressive scale −0.75 0.622 −0.051 0.735
MASQ anxious arousal 0.021 0.889 −0.098 0.519
MASQ general distress −0.146 0.332 0.155 0.305
MASQ anhedonia 0.015 0.620 0.151 0.316
TPQ novelty seeking 0.015 0.922 0.045 0.769
TPQ harm avoidance −0.164 0.277 0.099 0.511
TPQ reward dependence −0.191 0.204 0.179 0.234
BAS drive 0.165 0.273 −0.016 0.918
BAS fun 0.000 0.999 −0.139 0.356
BAS reward 0.004 0.977 −0.32 0.382
BIS −0.065 0.670 −0.091 0.549
BIS/BAS total 0.013 0.934 −0.144 0.341
LotR −0.072 0.635 0.012 0.935
IMI interest/enjoyment −0.075 0.620 −0.081 0.595
IMI perceived competence −0.280 0.060 −0.022 0.883
IMI effort/importance −0.142 0.346 −0.220 0.143
IMI pressure/tense −0.017 0.910 0.295 0.047
IMI choice −0.094 0.540 −0.197 0.194
IMI value/utility −0.343 0.020 −0.216 0.149
IMI total −0.339 0.021 −0.144 0.341
IRI fantasy −0.290 0.050 −0.016 0.915
IRI empathic concern −0.231 0.123 0.157 0.297
IRI perspective-taking −0.189 0.208 0.093 0.538
IRI personal distress 0.190 0.207 0.195 0.193
MISS suggestibility −0.165 0.274 0.254 0.089
MISS persuadability −0.060 0.693 −0.016 0.918
MISS physiological suggestibility −0.264 0.076 0.438 0.002
MISS physiological reactivity −0.354 0.016 0.159 0.292
MISS peer conformity −0.270 0.069 0.293 0.048
MISS mental control −0.220 0.141 0.005 0.975
MISS unpersuadability −0.121 0.421 0.295 0.047
MISS short suggestibility −0.284 0.056 0.175 0.245
MISS total −0.331 0.025 0.301 0.042
FOP severe −0.490 0.001 −0.073 0.629
FOP medical −0.416 0.004 −0.013 0.929
(Continued)
TABLE 2 | Continued
Personality traits PLACEBO EFFECT NOCEBO EFFECT
R p r p
FOP total −0.435 0.003 −0.037 0.806
PCS rumination −0.104 0.490 0.352 0.016
PCS magnification 0.032 0.831 0.054 0.721
PCS helplessness 0.021 0.887 0.366 0.012
PCS total −0.022 0.883 0.343 0.020
PSWQ −0.216 0.149 0.283 0.057
SS boredom susceptibility −0.066 0.661 0.098 0.518
SS disinhibition −0.031 0.839 −0.027 0.861
SS experience seeking 0.078 0.605 −0.093 0.537
SS adventure seeking −0.036 0.812 −0.025 0.869
SS total 0.014 0.924 0.005 0.976
STAI 1-2, State and Trait Anxiety Inventory; ASI, Anxiety Sensitivity Index; BAI, Beck
Anxiety Inventory; BDI, Beck Depression Inventory; PANAS, Positive and Negative
Affective Schedule; NEO, Neuroticism-Extraversion-Openness Inventory; MASQ, Mood
and Anxiety Symptom Questionnaire; TPQ, Tridimensional Personality Questionnaire;
BISBAS, Behavioral Inhibition and Behavioral Activation Scale; LotR, Life-Orientation Test-
Revisited; IMI, Intrinsic Motivation Inventory; IRI, Interpersonal Reactivity Index; MISS,
Multidimensional Iowa Suggestibility Scale; FOP, Fear of Pain; PCS, Pain Catastrophizing
Scale; PSWQ, Penn State Worry Questionnaire; SS, Sensation Seeking. Significant results
are indicated in bold.
expectancies: F(1, 44) = 1.860, p = 0.180; negative expectancies:
F(1, 44) = 0.025, p= 0.875].
Personality Predictors
We then explored the effects of personality factors on placebo
and nocebo effects. First, we ran a series of correlations analyses
and found that placebo responses were negatively correlated with
severity of anxiety (BAI: r =−0.485, p= 0.001), and fear of pain
(FOP, severe: r=−0.490, p= 0.001; medical fear, r=−0.416, p=
0.004; total fear r = −0.435, p = 0.003). By the contrary, nocebo
responses were positively correlated with anxiety sensitivity (ASI,
r = 0.460, p = 0.001), physiological suggestibility (MISS: r =
0.438, p= 0.002) with a trend for catastrophizing tendency (PCS
rumination: r = 0.352, p = 0.016; PCS helplessness: r = 0.366,
p= 0.012; PCS total: r = 0.343, p= 0.020) (Table 2).
Moreover, we considered the hypothesized psychological
factors taken together in order to identify their relationship
with the dependent variables (e.g., placebo and nocebo VAS)
using stepwise multiple regression models. The significant
values are reported in Tables 3, 4. Motivation (value/utility
and pressure/tense subscales) and suggestibility (physiological
reactivity and persuadability subscales) accounted for 51% of
variance in placebo responses (Table 3). Conversely, ASI, NEO-
openness-extraversion and depression taken together accounted
for 49.1% of variance in nocebo responses (Table 4).
Finally, we calculated mediation analyses for exploring
the relationship among personality factors, positive/negative
expectations and placebo/nocebo responses. Interestingly, we
found that expectations were significantly linked to placebo and
nocebo effects (see Table 5). However, personality factors per se
did not influence expectancies, and the indirect effect among
the three variables was not significant. Due to the exploratory
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TABLE 3 | Stepwise multiple regression models for the prediction of
placebo effects.
Dependent variable Predictor Variables R2 β t p
Placebo hypoalgesia Model 1 21.6
MISS physiol 0.464 3.438 0.001
Placebo hypoalgesia Model 1 21.6
MISS physiol 0.464 3.438 0.001
Model 2 35.4
MISS physiol 0.577 4.452 <0.001
IMI value −0.389 −2.999 0.005
Placebo hypoalgesia Model 1 21.6
MISS physiol 0.464 3.438 0.001
Model 2 35.4
MISS physiol 0.577 4.452 <0.001
IMI value −0.389 −2.999 0.005
Model 3 42.7
MISS physiol 0.579 4.687 <0.001
IMI value −0.371 −2.993 0.005
MISS persuadability 0.270 2.280 0.028
Placebo hypoalgesia Model 1 21.6
MISS physiol 0.464 3.438 0.001
Model 2 35.4
MISS physiol 0.577 4.452 <0.001
IMI value −0.389 −2.999 0.005
Model 3 42.7
MISS physiol 0.579 4.687 <0.001
IMI value −0.371 −2.993 0.005
MISS persuadability 0.270 2.280 0.028
Model 4 51.0
MISS physiol 0.463 3.745 0.001
IMI value −0.335 −2.871 0.007
MISS persuadability 0.344 3.006 0.005
IMI pressure 0.319 2.617 0.012
MISS, Multidimensional Iowa Suggestibility Scale (Physiological Reactivity and
Persuadability subscales); IMI, Intrinsic Motivation Inventory (Value/Utility and
Pressure/Tense subscales). Only significant values are shown. Excluded variables (not
significant): Lot-R, Life-Orientation Test-Revisited; BIS/BAS, Behavioral Inhibition and
Behavioral Activation Scale; IRI, Interpersonal Reactivity Index; SS, Sensation Seeking;
TPQ, Tri-dimensional Personality Questionnaire.
nature of this part of the study, we used a relative broad battery.
Therefore, correlations among personality questionnaires are
shown in Table 6.
DISCUSSION
In this study, we investigated the influence of expectations and
hypothesized psychological factors on placebo and nocebo effects
elicited by a well-established model of conditioning and heat
thermal painful stimulation. Placebo hypoalgesic responses were
negatively correlated with severity of anxiety and fear of pain
(e.g., medical fear, severe, and total fear). On the contrary, nocebo
hyperalgesic responses were positively correlated with anxiety
TABLE 4 | Stepwise multiple regression models for the prediction of
nocebo effects.
Dependent variable Predictor Variables R2 β t p
Nocebo hyperalgesia Model 1 20.3
ASI 0.451 3.349 0.002
Nocebo hyperalgesia Model 1 20.3
ASI 0.451 3.349 0.002
Model 2 33.3
ASI 0.498 3.966 <0.001
NEO_O −0.364 −2.897 0.006
Nocebo hyperalgesia Model 1 20.3 0.002
ASI 0.451 3.349
Model 2 33.3
ASI 0.498 3.966 <0.001
NEO openess −0.364 −2.897 0.006
Model 3 42.9
ASI 0.493 4.197 <0.001
NEO openess −0.472 −3.796 <0.001
NEO extraversion 0.329 2.660 0.011
Nocebo hyperalgesia Model 1 20.3
ASI 0.451 3.349 0.002
Model 2 33.3
ASI 0.498 3.966 <0.001
NEO openess −0.364 −2.897 0.006
Model 3 42.9
ASI 0.493 4.197 <0.001
NEO openess −0.472 −3.796 <0.001
NEO extraversion 0.329 2.660 0.011
Model 4 49.1
ASI 0.448 3.919 <0.001
NEO openess −0.413 −3.388 0.002
NEO extraversion 0.387 3.197 0.003
BDI 0.267 2.218 0.032
ASI, Anxiety Sensitivity Index; BDI, Beck Depression Inventory; NEO, Neuroticism-
Extraversion-Openness Inventory. Only significant values are shown. Excluded variables
(not significant for the model): STAI, State and Trait Anxiety Inventory; BAI, Beck Anxiety
Inventory; FOP. Fear of Pain; MASQ, Mood and Anxiety Symptom Questionnaire; PCS,
Pain Catastrophizing Scale; PSWQ, Penn State Worry Questionnaire; PANAS, Positive
and Negative Affective Schedule.
sensitivity, suggestibility and catastrophizing (trend only).
Moreover, a stepwise regression modeling showed that aggregate
scores of Motivation (value/utility and pressure/tense subscales)
and suggestibility (physiological reactivity and persuadability
subscales) accounted for the 51% of the variance in the placebo
responses. By contrast, the aggregation of anxiety, openness,
extraversion and depression accounted for the 49.1% of the
variance in the nocebo responses. Importantly, expectations
were highly correlated with placebo and nocebo effects and
psychological factors did not influence level of expectations
towards reduction or increase of pain.
Consistently with previous studies (Colloca and Benedetti,
2006, 2009; Colloca et al., 2008, 2010; Lui et al., 2010), we found
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TABLE 5 | Mediation analysis results.
Model a path b path c’ path Indirect
effect
BAI (X) p = 0.094 p = 0.018 p = 0.099 p = 0.184
Positive expectations (M)
Placebo hypoalgesia (Y)
FOP severe (X) p = 0.656 p = 0.005 p = 0.005 p = 0.673
Positive expectations (M)
Placebo hypoalgesia (Y)
FOP medical (X) p = 0.656 p = 0.011 p = 0.012 p = 0.309
Positive expectations (M)
Placebo hypoalgesia (Y)
FOP total (X) p = 0.217 p = 0.007 p = 0.012 p = 0.286
Positive expectations (M)
Placebo hypoalgesia (Y)
MISS physiol. (X) p = 0.181 p = 0.010 p = 0.078 p = 0.321
Negative expectations (M)
Nocebo hyperalgesia (Y)
ASI (X) p = 0.871 p < 0.001 p = 0.014 p = 0.879
Negative expectations (M)
Nocebo hyperalgesia (Y)
PCS rumination (X) p = 0.493 p = 0.023 p = 0.006 p = 0.539
Negative expectations (M)
Nocebo hyperalgesia (Y)
PCS help. (X) p = 0.322 p = 0.031 p = 0.022 p = 0.398
Negative expectations (M)
Nocebo hyperalgesia (Y)
PCS total (X) p = 0.350 p = 0.027 p = 0.014 p = 0.419
Negative expectations (M)
Nocebo hyperalgesia (Y)
BAI, Beck Anxiety Inventory; FOP, Fear Of Pain; MISS,Multidimensional Iowa Suggestibility
Scale; ASI, Anxiety Sensitivity Index; PCS, Pain Catastrophizing Scale.
that visual cues associated with prior experiences of low and high
pain elicit strong placebo and nocebo effects with a distribution
raging from no responses to low modulation of pain, to medium
and high reductions and increases (Figure 3). Studies on placebo
hypoalgesia and nocebo hyperalgesia have shown a substantial
inter-individual variability and distinct personality factors have
been associated with placebo and nocebo effects (Colloca and
Grillon, 2014; Colagiuri et al., 2015). There is evidence that some
personality factors such as anxiety (Staats et al., 2001; Ober et al.,
2012), fear of pain (Lyby et al., 2010) and neuroticism (Peciña
et al., 2013), are associated with reduced placebo analgesia. We
confirmed and expanded some of these findings. In our study,
severity of anxiety as well as fear of pain (e.g., medical, sever,
and total fear) were linked to reduced placebo responsiveness
to pain. Severity of anxiety including symptoms of depression,
feelings of hopelessness and irritability, guiltiness or feelings
of being punished, as well as physical symptoms such as
fatigue, correlated negatively with placebo responses with higher
severity of anxiety linked to lower reduction of pain induced by
positive expectations. High levels of fear of pain referring to the
dispositional tendency to have negative emotions toward pain
and pain anticipation have been also associated with placebo- and
nocebo-induced painmodulation (Lyby et al., 2010; Aslaksen and
Lyby, 2015). We found that fear of medical pain in particular
correlates with low placebo hypoalgesic responses and this is
consistent with the parallel enhancement of nocebo induced by
fear of pain and other medical procedures (Aslaksen and Lyby,
2015).
When we looked at the nocebo effect—the negative
counterpart of the placebo phenomenon (Petrovic, 2008)—we
found a positive correlation with anxiety sensitivity, physiological
suggestibility and catastrophizing. Anxiety sensitivity refers to
behaviors or sensations associated with the experience of anxiety
that elicit misinterpretations of bodily sensations such as the
experience of a no harmful stimulus causing intense pain
(Mehta et al., 2016). Suggestibility is a trait-like characteristic
creating distinct behaviors that facilitate responsiveness to
plausible information as well as inclinations to accept and act
on others’ suggestions in regards to the body (e.g., physical
suggestibility), and has been linked to placebo effects (Lund et al.,
2015) and nocebo effects (Corsi et al., 2016). Catastrophizing, a
maladaptive cognitive process that is potentially heritable and
has been reported to predict severity of clinical pain (Flor and
Turk, 1988; Severeijns et al., 2001; Goubert et al., 2004; Kudel
et al., 2005; Trost et al., 2015), has been recently explored and
shown to be relevant for nocebo effects (Vogtle et al., 2013).
Personality is a continuum of factors and thus highlights the
importance of considering distinct factors together. Therefore,
based on the literature we took into consideration two
sets of psychological factors related to placebo and nocebo
responsiveness and used a multilevel modeling approach in
which hierarchies and residual components at each level
within a hierarchy are computed. Such an approach indicated
that an aggregate score for motivation (value/utility and
pressure/thanks subscales) and suggestibility (physiological
reactivity and persuadability subscales) accounted for the 51%
of the variance in the placebo hypolagesic responses whilst
anxiety severity, NEO-openness-extraversion and depression
considered together accounted for the 49.1% of the variance
of nocebo responses suggesting that it helps evaluate the
psychological factors comprehensively. Another important result
from this study was that positive expectations were significantly
correlated with placebo responses and negative expectations were
significantly correlated with nocebo responses. Although one
may argue that asking on a trial-by-trial about expectancy of the
upcoming pain may have generated a sort of self-prophecy (e.g.,
You get what you expect, you get what you ask for), it remains
an interesting finding that could be important to keep in mind
every time we measure pain in real-world settings. Therefore,
an obvious question was whether personality factors impact the
formation of expectations of pain reduction and increase. In
this study, mediation analyses indicated that personality factors
(e.g., being worried, being fearful) had no direct effect on the
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level of expectation related to pain changes (e.g., reductions and
increases). Future large scale studies deserve to be performed in
pain patient and healthy populations to better understand the
connection among psychological factors, expectancies, placebo
and nocebo effects.
The inclusion of an extensive battery of questionnaires related
to personality factors allowed us to reveal that expectations may
predict placebo and nocebo effects independently of personality
factors making it a helpful tool for health care providers.
Several studies have emphasized the need for exploring the
impact of personality factors as at least one of the possible
ways to interpret and understand the large variability in
placebo analgesic and nocebo hyperalgesic responses. To our
knowledge, this is the first study that explores how distinct
psychological factors can predict placebo hypolagesic responses
and nocebo hyperalgesic responses, and the potential influence of
personality factors in shaping positive and negative expectancies.
Collectively, the complexity and variability in placebo- and
nocebo-induced pain responses highlight a need to better
understand the multidimensionality of pain and its modulation
related to individual expectations and psychological factors. This
approach provides advantages in interpreting how pain is felt and
experienced.
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